TRANSGENICALLY PRODUCED BIOPHARMACEUTICALS COULD SOAR TO
With the possibility of the world's first transgenic plant-produced biopharmaceutical
being approved for use this year, worldwide attention is focusing on the futuristic
breakthroughs that could dramatically alter the biopharm manufacturing landscape
and drive sales past the $12 billion mark by 2012. This is according to a new
study from market research firm Kalorama Information, a division of MarketResearch.com,
a leading provider of industry-specific market research reports.